alert-system

huifer's avatarfrom huifer

Automated alert system for key events in drug discovery. Use for trackingcompetitor milestones, clinical trial updates, regulatory decisions, andpublications of interest.Keywords: alerts, monitoring, tracking, notifications, competitive intelligence

⭐0stars🔀0forks📁View on GitHub🕐Updated Jan 4, 2026
[Market Research]

When & Why to Use This Skill

This Claude skill is a specialized intelligence agent designed for the pharmaceutical and biotech industries to automate the monitoring of the drug discovery landscape. It streamlines competitive intelligence by tracking clinical trial milestones, regulatory decisions, patent filings, and scientific publications, delivering structured reports and real-time alerts to help teams stay ahead of market shifts.

Use Cases

  • Competitive Intelligence: Track competitor pipeline updates, M&A activities, and new patent filings to maintain a strategic advantage in specific therapeutic areas.
  • Clinical Trial Monitoring: Automatically follow status changes and primary endpoint results on ClinicalTrials.gov for specific drug targets like EGFR inhibitors.
  • Regulatory Tracking: Receive immediate notifications regarding FDA or EMA decisions, including drug approvals, rejections, and clinical hold updates.
  • Academic & Literature Surveillance: Stay informed on high-impact scientific publications and conference abstracts from PubMed and major medical congresses (e.g., ASCO, ESMO) relevant to your research targets.
namealert-system
description|
Keywordsalerts, monitoring, tracking, notifications, competitive intelligence
categoryIntelligence
tags[alerts, monitoring, notifications, tracking]
version1.0.0
authorDrug Discovery Team

Alert System Skill

Automated monitoring and alerting for drug discovery intelligence.

Quick Start

/alerts --create --target "EGFR inhibitors" --events clinical,fda
/alerts --list
/alerts --check my-alert

What's Included

Alert Type Description Sources
Clinical Updates Trial status changes ClinicalTrials.gov
Regulatory FDA/EMA decisions FDA, EMA
Publications New papers on target PubMed
Competitor Pipeline updates Press releases
Patent New patent filings USPTO, EPO
Conference Meeting abstracts ASCO, ESMO

Alert Configuration

name: EGFR Competitive Alerts
description: Monitor EGFR inhibitor landscape

targets:
  - EGFR
  - Exon 19 deletion
  - T790M
  - C797S

competitors:
  - AstraZeneca
  - Johnson & Johnson
  - Roche

events:
  - clinical_trial_updates
  - regulatory_approvals
  - publications
  - patent_filings

filters:
  phase: [2, 3]
  countries: [US, EU, CN, JP]
  minimum_significance: high

notifications:
  email: user@example.com
  frequency: weekly
  format: summary

Output Structure

# Alert Report: EGFR Landscape (Weekly)

## Summary
| Alert Type | New | Total |
|------------|-----|-------|
| Clinical Updates | 3 | 127 |
| Publications | 12 | 456 |
| Regulatory | 1 | 23 |
| Patent Filings | 5 | 89 |

## Clinical Trial Updates

### New Trials
| NCT ID | Sponsor | Phase | Indication | Status |
|--------|---------|-------|------------|--------|
| NCT01234567 | AstraZeneca | 3 | NSCLC | Recruiting |
| NCT01234568 | Johnson & Johnson | 2 | NSCLC | Not recruiting |

### Status Changes
| NCT ID | Previous | Current | Date |
|--------|----------|---------|------|
| NCT07890123 | Recruiting | Active, not recruiting | 2024-12-10 |

## Key Publications

1. **Fourth-generation EGFR inhibitors targeting C797S**
   - Journal: Nature Cancer
   - Date: 2024-12-08
   - Authors: Zhang et al.
   - Impact: Novel scaffold for resistance

2. **Combination therapy: EGFR + MET inhibition**
   - Journal: Lancet Oncology
   - Date: 2024-12-05
   - Authors: Smith et al.
   - Impact: Positive Phase 2 results

## Regulatory Updates

### FDA Actions
| Date | Sponsor | Action | Drug |
|------|---------|--------|------|
| 2024-12-12 | AstraZeneca | Approval | Tagrisso (adjuvant) |

## Patent Filings

### New Patents
| Date | Assignee | Title | Patent No. |
|------|----------|-------|------------|
| 2024-12-10 | Merck | EGFR C797S inhibitors | US2024/XXX |
| 2024-12-08 | Roche | Antibody-drug conjugate | EPXXX |

## Recommendations

**Action Items**:
1. Review new C797S inhibitor paper - assess differentiation
2. Monitor AstraZeneca adjuvant approval impact
3. Investigate Merck's new patent - potential FTO issue

Event Types

Event Description Priority
Clinical trial starts New trial initiated Medium
Clinical trial completes Primary endpoint reached High
Regulatory approval Drug approval High
Regulatory rejection CRL, rejection High
Key publication High-impact paper Medium
Competitor deal M&A, licensing High
Patent granted New patent issued Medium
Patent expiry Patent expires Low

Running Scripts

# Create new alert
python scripts/alert_system.py --create my-alert --target "EGFR"

# Check for updates
python scripts/alert_system.py --check my-alert

# List all alerts
python scripts/alert_system.py --list

# Export alert history
python scripts/alert_system.py --export my-alert --format csv

Requirements

pip install requests schedule

# For persistence
pip install sqlalchemy

Reference

Best Practices

  1. Set specific targets: Narrower = fewer false positives
  2. Use appropriate frequency: Daily for high-priority, weekly for others
  3. Review regularly: Alerts need human interpretation
  4. Adjust filters: Refine based on signal-to-noise
  5. Document actions: Track alert-driven decisions

Common Pitfalls

Pitfall Solution
Too many alerts Narrow target/event filters
False positives Add confidence filters
Alert fatigue Adjust frequency and thresholds
Missing context Include summary with links
No action tracking Document response to alerts

Alert Frequency Guidelines

Priority Check Frequency Notification
Critical Hourly Immediate
High Daily Daily digest
Medium Weekly Weekly summary
Low Monthly Monthly report